Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
April 04, 2024 16:00 ET
|
Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
March 09, 2024 12:00 ET
|
Alumis Inc
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024.
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
March 06, 2024 08:00 ET
|
Alumis Inc
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors – – Proceeds will support ongoing comprehensive mid to...
Immunology Collaboration and Licensing Agreements Analysis Report 2023
November 17, 2023 06:13 ET
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
November 09, 2023 16:05 ET
|
Exagen Inc.
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the...
Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
November 08, 2023 15:37 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 08, 2023 (GLOBE NEWSWIRE) -- [Exton PA, November 8, 2023] — Spherix Global Insights recently conducted research with 306 Systemic Lupus Erythematosus (SLE) patients,...
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
October 17, 2023 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
Addressing Unmet Needs: The SLE Market Grows as Research and Development Flourish
October 06, 2023 06:08 ET
|
Research and Markets
Dublin, Oct. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market (by Product Type, Route of Administration, End User, & Region): Insights & Forecast with...
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
July 27, 2023 16:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists with...
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 25, 2023 16:05 ET
|
Exagen Inc.
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before...